# GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis

> **NCT03474042** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 22 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** GLPG2737
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03474042
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-29
- **Primary completion:** 2018-04-10
- **Final completion:** 2018-04-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474042, "GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03474042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*